Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Recurrence 2Polycystic Ovary Syndrome 2Pleural Effusion, Malignant 2Neoplasms 2Neoplasm Metastasis 2Mesothelioma, Malignant 2Triple Negative Breast Neoplasms 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 126Carboplatin 108Pemetrexed 76Paclitaxel 76Cisplatin 73Nivolumab 56Docetaxel 53Erlotinib Hydrochloride 50Gemcitabine 49Radiotherapy 48Bevacizumab 32osimertinib 31Cetuximab 29atezolizumab 25Cyclophosphamide 25durvalumab 24130-nm albumin-bound paclitaxel 22Oxaliplatin 19Fluorouracil 18Taxes 17Radiosurgery 17fludarabine 16Magnetic Resonance Spectroscopy 16Gefitinib 16Ipilimumab 15Vinorelbine 14Leucovorin 14Albumin-Bound Paclitaxel 14Vorinostat 13Radiation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Non-Small-Cell Lung × Pharmaceutical Preparations × Clear all
NCT03401385 2025-10-21

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Daiichi Sankyo

Phase 1 Active not recruiting
890 enrolled
BreastThoracic

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡